While Roche has an early lead, Quest recently made key moves to improve its position in the AD patient-initiated blood testing market.
Protein levels in the vitreous humor may have the potential to support the diagnosis and staging of neurodegenerative diseases.
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
In this month’s diagnostics pipeline report, Roche gets clearance for two new Alzheimer’s early detection tests.
A recent study led by a team at the University of Gothenburg shows that multiple biomarkers could ID the disease even in people with no symptoms.